Changing the way we do business: Recommendations to accelerate biomarker development in pancreatic cancer

Margaret A. Tempero, David Klimstra, Jordan Berlin, Tony Hollingsworth, Paula Kim, Nipun Merchant, Malcolm Moore, Doug Pleskow, Andrea Wang-Gillam, Andrew M. Lowy

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Pancreatic ductal adenocarcinoma is the most aggressive of all epithelial malignancies. In contrast to the favorable trends seen in most other common malignancies, the five-year survival of patients with this disease remains only 6%, a statistic that has changed minimally for decades. Only two drugs have been approved by the U.S. Food and Drug Administration (FDA) for use in pancreatic cancer in the last 15 years, and there are no established strategies for early detection.

Original languageEnglish (US)
Pages (from-to)538-540
Number of pages3
JournalClinical Cancer Research
Volume19
Issue number3
DOIs
StatePublished - Feb 1 2013
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tempero, M. A., Klimstra, D., Berlin, J., Hollingsworth, T., Kim, P., Merchant, N., Moore, M., Pleskow, D., Wang-Gillam, A., & Lowy, A. M. (2013). Changing the way we do business: Recommendations to accelerate biomarker development in pancreatic cancer. Clinical Cancer Research, 19(3), 538-540. https://doi.org/10.1158/1078-0432.CCR-12-2745